The efficacy of xamoterol in heart failure of ischemic origin

Journal of Cardiovascular Pharmacology

Volumn 14, Issue , 1989, Pages S69-S72

  Marlow, Hilary F ^a  

^a AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

XAMOTEROL;

CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY;

ADRENERGIC BETA-AGONISTS; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMAN; PROPANOLAMINES; XAMOTEROL;

EID: 0024439241     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-198900145-00012     Document Type: Article

References (29)

1. Heikkila J. The clinical dilemma of the patient with angina pectoris and heart failure. Practical Cardiol 1986;12:54-6.
2. Bonow RO, Vitale DF, Bacharach SL, Frederick TM, Kent KM, Green MV. Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty. Circulation 1985;71:297-307.
3. McLaurin LP, Rolett EL, Grossman W. Impaired left ventricular relaxation during pacing-induced ischemia. Am J Cardiol 1973;32:751-7.
4. Pouleur H, Rousseau MF, van Eyll C. Impaired regional diastolic distensibility in coronary artery disease: relations with dynamic left ventricular compliance. Am Heart J 1986; 112:721-8.
5. Soufer R, Wohlgelernter D, Vita NA, et al. Intact systolic left ventricular function in clinical congestive heart failure. Am J Cardiol 1985;55:1032-6.
6. 1-adrenoceptor partial agonist. Br J Pharmacol 1982:77:381-8.
7. 1-partial agonist (Corwin) on left ventricular function and myocardial metabolism in patients with previous mvocar-dial infarction. Am J Cardiol 1983:51:1267-74.
8. De Feyter PJ, Serruys PW. Hemodynamic effects of xamoterol at rest and during exercise in patients with chronic post-infarction angina: a randomised trial. Eur Heart J 1988:9:181.
9. Detry JMR, Decoster PM, Brasseur A. Hemodynamic effects of "Corwin" (ICI 118.587), a new cardioselective beta-adreno-ceptor partial agonist. Eur Heart J 1983;4:584-91.
10. Pouleur H, Detry JM, Mancia G. Inotropic drugs of the future [Editorial]. Eur J Clin invest 1982:12:441-3.
11. Marlow HF, Harry JD, Shields AG. Duration of action of single intravenous doses of ICI 118.587. A cardiac beta-stimulant. World Conference on Clinical Pharmacology and Therapeutics, London, 1980, Abstract 0772.
12. Marlow HF. Wardleworth AG, Booth LM. The haemodyna-mic effects of oral doses of ICI 1 18,587, a beta-adrenoceptor partial agonist in healthy volunteers. Br J Clin Pharmacol 1982;13:269P-70.
13. Harry JD, Marlow HF, Wardleworth AG, Young J. The action of ICI 118,587 (a beta-adrenoceptor partial agonist) on the heart rate response to exercise in man. Br J Clin Pharmacol 1981;12:266P.
14. Tango M, Carlsen JE. Trap-Jensen J. Immediate central and regional haemodynamic effects of a new beta,-adrenergic stimulating drug, xamoterol (Corwin), in healthy volunteers. Eur J Clin Pharmacol 1985;29:155-8.
15. Jennings G, Bobik A, Oddie C, Restall R. Cardioselectivity, kinetics, hemodynamics and metabolic effects of xamoterol. Clin Pharmacol Ther 1984;35:594-603.
16. 1-adrenoceptor partial agonist ICI 118,587 on left ventricular function in patients with coronary artery disease. Int J Cardiol 1984;5:339-49.
17. Detry JMR, Decoster PM, Buy JJ, Rousseau MF, Brasseur LA. Antianginal effects of "Corwin", a new beta-adrenoceptor partial agonist. Am J Cardiol 1984;53:439-43.
18. Barrios L, Geboers J, Piessens JH, de Geest H. Effects of xamoterol, a new beta-adrenoceptor antagonist in patients with angina pectoris. Eur J Clin Pharmacol 1986;29:667-71.
19. Beatt KJ, Saltissi S, Keiles PJ, Adams PC, Julian DG. Effects of xamoterol ("Corwin") in patients with heart failure secondary to ischaemic heart disease [Abstract]. Circulation 1985;72(suppl II):II-473.
20. 1-adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J 1985;54:17-21.
21. Molajo AO, Bennett DH, Marlow HF, Snow HM, Bastain W. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease. Br J Clin Pharmacol 1987;24:373-9.
22. Pouleur H, Van Eyll C. Hanet C. Cheron P. Charlier AA. Rousseau MF. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling: a study in patients with anterior myocardial infarction and single-vessel disease. Circulation 1988;77:1081-9.
23. Pouleur H, Van Eyll C, Hanet C, Cheron P. Charlier AA. Rousseau MF. Changes in left ventricular filling dynamics after long-term xamoterol therapy in ischemic left ventricular dysfunction. Heart Failure 1986;2:176-84.
24. Rousseau MF, Pouleur H, Nannan M, Detry JMR, Brasseur LA, Lavenne F. Improved physical capacity during ICI 118,587 administration in moderate heart failure: preliminary results after 1 year of follow-up [Abstract]. Eur Heart J 1984;5:(suppl I):267.
25. Rousseau MF, Gurne O, Caucheteux D, et al. Improvement of silent myocardial ischemia by the positive inotropic drug xamoterol [Abstract]. Circulation 1988;78(suppl II):II-454.
26. Blackwood R, Marlow HF. Xamoterol in the management of patients with exertional breathlessness and fatigue due to cardiac disease [Abstract]. J Am Coll Cardiol 1988;11:143A.
27. The German and Austrian Xamoterol Study Group. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet 1988;1:489-93.
28. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22.
29. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.